Love it or hate it, it's BLUE.
Anecdotal, non-scientific evidence of a serious side effect prompted a halt of a trial of a product, and the company is investigating. No one knows anything else until the company reports. End. Of. Story.
There is a strong bid today, and here you can see why. BLUE has clipped long-term support and bounced nicely off of it for it's largest intraday gain in (what seems like) a long time.
My bet is that BLUE now remains in this ascending channel, which should entail some enjoyable rallies and frustrating pullbacks. You can sell $20/$25 put spreads and sleep at night, and the gamblers among you can buy calls in the upper half of the channel.
Bon voyage, BLUE.
Anecdotal, non-scientific evidence of a serious side effect prompted a halt of a trial of a product, and the company is investigating. No one knows anything else until the company reports. End. Of. Story.
There is a strong bid today, and here you can see why. BLUE has clipped long-term support and bounced nicely off of it for it's largest intraday gain in (what seems like) a long time.
My bet is that BLUE now remains in this ascending channel, which should entail some enjoyable rallies and frustrating pullbacks. You can sell $20/$25 put spreads and sleep at night, and the gamblers among you can buy calls in the upper half of the channel.
Bon voyage, BLUE.